TENX Heartened, AXGN Sees 40% Revenue Growth, Mark Your Calendar For REPH

Tenax Therapeutics Inc. gained 128.45% on Thursday, following promising results of a preclinical study of Levosimendan, published in the journal named Pulmonary Circulation. The results suggest that chronic administration of Levosimendan improves right heart function.

from RTT - Biotech http://ift.tt/2HWAoz6
via IFTTT